| Project/Area Number |
16K09558
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
原 弘道 東京慈恵会医科大学, 医学部, 講師 (70398791)
|
|---|
| Research Collaborator |
HARA HIROMICHI
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 尿中PGE-MUM / 肺腺癌 / PGE-MUM / 肺癌 |
|---|
| Outline of Final Research Achievements |
Prostaglandin E- major urinary metabolite (PGE-MUM) levels were significantly elevated in patients with lung adenocarcinoma. PGE-MUM level of 14.9 μg/g・Cr showed 70.4% sensitivity and 67.7% specificity for diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression determined by TNM staging system. Advanced stage (stageⅢ, stageⅣ,recurrence) was significantly associated with high PGE-MUM by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and CEA levels. PGE-MUM can be a promising biomarker reflecting systemic tumor burden of lung adenocarcinoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
尿中PGE 代謝産物（prostaglandin E-major urinary metabolite: PGE-MUM）は肺腺癌患者で増加していた。PGE-MUMは14.9 g/g・Crをカットオフとすると肺腺癌の診断感度70.4％、特異度67.7％であった。PGE-MUMは肺癌の進展ともに増加する傾向であった。肺癌が進行期であることは有意にPGE-MUM高値と関連した。PGE-MUMとCEAは相関がみられなかった。PGE-MUMは肺腺癌の腫瘍量を反映する新たなバイオマーカーとなる可能性がある。
|
